NADMED platform sets reference ranges for blood NAD and glutathione
A large population study using NADMED’s redox metabolite testing platform has established healthy reference ranges for NAD and glutathione, two key drivers of cellular energy metabolism, and identified distinct disease-related alterations in both from a single blood sample.
The study, published in Redox Biology, was led by researchers at the University of Helsinki with co-authors from NADMED. It draws on data from 330 healthy adults aged 18 to 70. Applying the same platform to patient biobank samples, the researchers found disease-associated alterations in NAD and glutathione levels, and found that systemic NAD does not decline with healthy aging.
“Establishing what a normal NAD and glutathione profile looks like has been a missing piece for the field,” says Anu Suomalainen Wartiovaara, professor at the University of Helsinki. “Now the individuals whose levels are substantially altered can be identified.”
NADMED’s CE-marked platform quantifies all six key NAD- and glutathione-related metabolites from a single blood sample using standard laboratory methods.
“This strengthens the foundation for expanding our work with laboratories, clinics, and pharma and biotech partners worldwide,” says James Lee, CEO of NADMED.
Published: September 14, 2026
